<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List href="gencinme_dosyalar/filelist.xml">
<link rel=Edit-Time-Data href="gencinme_dosyalar/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>GEN�LERDE &#304;NME</title>
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>125</w:Zoom>
  <w:GrammarState>Clean</w:GrammarState>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h2
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:10.0pt;
	font-family:"Times New Roman";}
h3
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h4
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:71.25pt;
	margin-bottom:.0001pt;
	text-indent:-18.0pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:10.0pt;
	font-family:"Times New Roman";}
h5
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:5;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin:0cm;
	margin-bottom:.0001pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:8;
	font-size:9.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:72.0pt;
	margin-bottom:.0001pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:9;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:108.0pt;
	margin-bottom:.0001pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.title1, li.title1, div.title1
	{mso-style-name:title1;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:41.25pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.authors1, li.authors1, div.authors1
	{mso-style-name:authors1;
	margin-top:3.6pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:41.25pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.source1, li.source1, div.source1
	{mso-style-name:source1;
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:4.2pt;
	margin-left:41.25pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.links1, li.links1, div.links1
	{mso-style-name:links1;
	margin-top:4.2pt;
	margin-right:0cm;
	margin-bottom:4.2pt;
	margin-left:41.25pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.pmid1, li.pmid1, div.pmid1
	{mso-style-name:pmid1;
	margin-top:4.2pt;
	margin-right:0cm;
	margin-bottom:4.2pt;
	margin-left:41.25pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	color:dimgray;}
span.msons
	{mso-style-name:mso\0131ns;
	text-decoration:underline;
	text-underline:single;}
span.msodel0
	{mso-style-name:msodel;
	color:red;
	text-decoration:line-through;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:197931842;
	mso-list-template-ids:-1776376006;}
@list l1
	{mso-list-id:1261530302;
	mso-list-template-ids:1186495216;}
@list l1:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2
	{mso-list-id:1614558665;
	mso-list-template-ids:1056447414;}
@list l2:level1
	{mso-level-start-at:2;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3
	{mso-list-id:1792747130;
	mso-list-template-ids:-2137477698;}
@list l3:level1
	{mso-level-start-at:2;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>GEN�LERDE &#304;NME</span></b></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Rezzan TUNCAY</span></b></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Son G�ncelle&#351;tirme Tarihi: <b>28.5.2009</b></span></p>

</div>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;NS&#304;DENS</span></b></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>K&#305;rkbe&#351;<span style='color:red'> </span>ya&#351;&#305;n
alt&#305;nda g�r�len inmeler gen�&nbsp; inme olarak
s&#305;n&#305;fland&#305;r&#305;l&#305;r. Gen�lerde inme insidensi 2,5 - 40 /
100.000<span style='color:red'> </span>aras&#305;nda de&#287;i&#351;mektedir.
B�t�n inmelerin % &nbsp;4 -10 kadar&#305; gen�lerde g�r�l�r. Erkeklerde 30
ya&#351;&#305;n �st�nde, kad&#305;nlarda ise 30 ya&#351;&#305;ndan daha gen�
olanlarda inme insidensi y�ksektir<span style='color:red'>.</span> Bu fark 30
ya&#351;&#305;n alt&#305;ndaki kad&#305;nlarda gebelik, oral kontraseptif
kullan&#305;m&#305;na ba&#287;l&#305; inmelerin daha s&#305;k g�r�lmesindendir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ETYOLOJ&#304;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�e&#351;itli �al&#305;&#351;malarda inme
etyolojileri aras&#305;nda b�y�k farkl&#305;l&#305;klar g�r�lmektedir.
Etyolojik fakt�rler dikkatle ara&#351;t&#305;r&#305;ld&#305;&#287;&#305;nda en
s&#305;k neden kardioembolizmdir. Bunu arteryel diseksiyon ve b�y�k damar
aterosklerozu<span style='color:red'> </span>izler. Gen�lerde inmeye neden olan
etyolojik nedenlerin da&#287;&#305;l&#305;m&#305; Tablo 1�de g�r�lmektedir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 1.&nbsp; Gen�lerde inmeye neden olan
etyolojik nedenler (Kaynak 2�den de&#287;i&#351;tirilerek)&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>I. ARTERYEL
HASTALIKLAR</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:35.4pt;line-height:150%'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>1. ATEROSKLEROZA BA&#286;LI</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:35.4pt;line-height:150%'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;2. NONATEROSKLEROT&#304;K <span style='color:red'>&nbsp;</span>HASTALIKLAR</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:72.0pt;line-height:150%;page-break-after:
avoid'><b><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'>A-</span></b><b><span lang=TR style='font-size:
7.0pt;line-height:150%;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></b><b><span lang=TR style='font-size:10.0pt;line-height:150%;
font-family:Tahoma;mso-ansi-language:TR'>NON&#304;FLAMATUVAR</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;line-height:150%;page-break-after:
avoid'><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;
mso-ansi-language:TR'>Diseksiyon</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;line-height:150%;page-break-after:
avoid'><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;
mso-ansi-language:TR'>Fibrom�sk�ler displazi</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;line-height:150%;page-break-after:
avoid'><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;
mso-ansi-language:TR'>Moyamoya</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:70.8pt;line-height:150%'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INFLAMATUVAR</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;line-height:150%'><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;Takayasu hastal&#305;&#287;&#305;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;line-height:150%'><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&#304;nfektif arterit &nbsp;(sifiliz, tbc, AIDS, vs.)</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:108.0pt;line-height:150%'><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;Sistemik vask�lit<span style='color:red'> </span>(poliarteritis
nodosa, Beh�et hast, SLE, romatoid arterit)</span></p>

<p class=MsoNormal style='margin-left:108.0pt;line-height:150%'><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>II-HEMATOLOJ&#304;K
&nbsp;HASTALIKLAR</span></b></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt;line-height:
150%'><b><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'>H&#304;PERV&#304;SKOZ&#304;TE ( &nbsp;</span></b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Miyeloproliferatif hastal&#305;klar ) </span></p>

<p class=MsoNormal style='margin-left:70.8pt;line-height:150%'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>KOAG�LOPAT&#304;<span style='color:red'> </span></span></b><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>( protein C, protein &nbsp;S ve antitrombotin III eksikli&#287;i,
Fakt�r&nbsp; V Leiden mutasyonu, antifosfolipid antikor sendromu, oral
kontraseptif, gebelik, puerperium, trombositoz, polisitemia vera, orak h�creli
anemi, homosistinemi ve homosistin�ri )&nbsp; </span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt;line-height:
150%'><b><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'>ANEM&#304;</span></b></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>III- KALP HASTALIKLARI</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:34.8pt;line-height:
150%'><b><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'>VALV�LER:</span></b><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'> Mitral stenoz, protez kapak, mitral kapak prolapsusu</span></p>

<p class=MsoNormal style='margin-left:70.8pt;text-indent:2.25pt;line-height:
150%'><b><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'>D&#304;&#286;ER </span></b><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>: Atrial fibrilasyon, hasta sin�s sendromu, akut miyokard infarkt�s�,
atriyal septal defekt, sol atrial miksoma,atrial septal anevrizma</span></p>

<p class=MsoNormal style='text-indent:2.25pt;line-height:150%'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>IV- GENET&#304;K&nbsp; HASTALIKLAR</span></b></p>

<p class=MsoNormal style='margin-left:70.8pt;line-height:150%'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>CADASIL</span></b></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:34.8pt;line-height:
150%'><b><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'>M&#304;TOKONDR&#304;YAL HASTALIKLAR (MELAS )</span></b></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>V-&nbsp;
M&#304;GREN / &#304;NME</span></b><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>VI- D&#304;&#286;ER &nbsp;NEDENLER</span></b><span lang=DE
style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.4pt;text-indent:35.4pt;line-height:
150%'><b><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'>&#304;LA�LAR </span></b><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>(Antiinflamatuvar ila�lar , sildenafil, atipik antipisikotikler vs)</span><span
lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:34.8pt;line-height:
150%'><b><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'>K�T�YE KULLANILAN MADDELER</span></b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'> (<b> </b>Kokain, amfetamin vs )</span><span lang=DE style='mso-ansi-language:
DE'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>PROGNOZ</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Prognoz altta yatan etyolojik nedene
ba&#287;l&#305;d&#305;r. Uzun s�reli prognozda inme i�in risk fakt�rlerinin<span
style='color:red'> </span>bulunup bulunmamas&#305; seyri etkiler.
Aterosklerotik vask�ler hastal&#305;&#287;a ba&#287;l&#305; ge�ici iskemik atak
(G&#304;A)�larda inme, miyokard infarkt�s� (MI) ve mortalite riski y�ksektir.
Migren �yk�s�n�n bulunmad&#305;&#287;&#305;, incelemelerin negatif oldu&#287;u
G&#304;A�larda ise rek�rren inme riski d�&#351;�kt�r. Gen�lerde rek�rren inme
oran&#305; etyolojik nedene ba&#287;l&#305; olmakla birlikte y&#305;lda %1�den daha
azd&#305;r. &#304;nmenin akut d�neminde mortalite oran&#305; &nbsp;%1,5-7,3
aras&#305;nda de&#287;i&#351;mektedir. &#304;zleme s&#305;ras&#305;nda
hastalar&#305;n&nbsp; yar&#305;dan fazlas&#305; �nceki aktivitelerine
d�nebilir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ETYOLOJ&#304;K
&#304;NCELEMELER</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Akut yerle&#351;en fokal n�rolojik bulgu ile gelen
gen� hastalar&#305;n yakla&#351;&#305;k 1/3�inde beyin damar
hastal&#305;&#287;&#305; d&#305;&#351;&#305; nedenler s�z konusudur. Akut
n�rolojik bulgusu olan bir hastaya ilk olarak Bilgisayarl&#305; Tomografi (BT)
veya kanamaya duyarl&#305; sekanslar&#305; da i�eren magnetik rezonans
g�r�nt�leme&nbsp; (MR) ( Bak&#305;n&#305;z: <u><span style='color:blue'>Beyin
Kanamalar&#305;</span></u> ) ve <b>Tablo 2</b>�de g�sterilen incelemeler
yap&#305;lmal&#305;d&#305;r. Bu &#351;ekilde iskemik, hemorajik inme
ay&#305;r&#305;m&#305; yap&#305;labilir. Ayr&#305;ca vask�ler hastal&#305;k
d&#305;&#351;&#305;<span style='color:red'> </span>nedenler
d&#305;&#351;lanabilir. Akut n�rolojik defisitin beyin damar
hastal&#305;&#287;&#305;na ba&#287;l&#305; oldu&#287;una karar verildikten
sonra inme mekanizmas&#305;n&#305; ayd&#305;nlatmaya y�nelik incelemeler
yap&#305;lmal&#305;d&#305;r. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
9.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 2.&nbsp; Akut
n�rolojik bulgusu olan bir hastada ilk inceleme plan&#305;</span></b></p>

<div class=MsoNormal align=center style='text-align:center;line-height:150%;
page-break-after:avoid'><span lang=TR style='font-size:10.0pt;line-height:150%;
font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Kranyal BT</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Tam kan
say&#305;m&#305;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Trombosit
say&#305;m&#305;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Kan &#351;ekeri</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Elektrolitler</span><span
lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Karaci&#287;er
fonksiyon testleri</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Kan �resi ve
kreatinin</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>PT ve aPTT</span><span
lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Sedimentasyon
, CRP</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>EKG</span><span
lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&#304;drar
tahlili</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Trigliserid ve
kolesterol</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Transtorasik
ekokardiyografi (TTE )</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center;line-height:150%'><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>1. Vask�ler
&#304;ncelemeler</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gen� hastalarda iskemik inme en s&#305;k embolik
dal okl�zyonuna, b�y�k damar aterosklerozuna<span style='color:red'> </span>ve
arteryel diseksiyona ba&#287;l&#305; olarak geli&#351;ir. &#304;nmenin erken
d�neminde konvansiyonel anjiografi yap&#305;lmas&#305; iskemik inmenin nedenini
ortaya koyabilir. E&#287;er konvansiyonel anjiografi yap&#305;lacaksa, m�mk�n
olan en erken zamanda&nbsp; yap&#305;lmal&#305;d&#305;r. Ekstrakranyal ve
transkranyal Doppler US incelemesi iskemik inmeli bir hastada tarama testi
olarak kullan&#305;labilir. &#304;ntrakranyal Magnetik Rezonans Anjiografi
(MRA) ise intrakranyal dola&#351;&#305;m&#305; g�stermede her zaman yeterli
olmamaktad&#305;r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>2. Kardiyolojik
&#304;ncelemeler</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gen� inmeli hastalar&#305;n 1/3�inde inme nedeni
kardiyoemboliktir. &#304;ncelemeler kardiyak de&#287;erlendirme, EKG, 24
saatlik ritim Holter monitorizasyonu ve ekokardiyografiyi i�ine
almal&#305;d&#305;r. Transtorasik ekokardiyografi (TTE)&nbsp; normal ise veya
sol atriuma ait bir patoloji d�&#351;�n�l�yorsa, trans�zofageal ekokardiyografi
(TEE) , parodoksal&nbsp; emboliyi ara&#351;t&#305;rmak i�in de intraven�z eko
kontrast ile<span style='color:red'> </span>TEE yap&#305;lmal&#305;d&#305;r.
TEE�de sa&#287; atriumdan sola&nbsp; �shunt� g�sterilebilir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>3. Hematolojik
&#304;ncelemeler</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ba&#351;lang&#305;�ta yap&#305;lan tarama
testlerinde orak h�creli anemi, polisitemi gibi nedenler yoksa, iskemik inmenin
nedeni bulunamam&#305;&#351;sa, hastada tekrarlayan inmeler varsa, inme
lokalizasyonu nadir g�r�len bir lokalizasyon ise,&nbsp; hastalar konjenital ve
edinsel koag�lopati nedenleri y�n�nden de&#287;erlendirilmelidir. Bu nedenle <b>Tablo
3</b>� de yer alan ileri hematolojik incelemeler yap&#305;lmal&#305;d&#305;r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%;page-break-after:avoid'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 3. Hematolojik
&nbsp;&#304;ncelemeler</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center;line-height:150%;
page-break-after:avoid'><span lang=TR style='font-size:10.0pt;line-height:150%;
font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Fibrinojen</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Fibrin
y&#305;k&#305;m �r�nleri</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>D-dimer</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Protein C,
Protein S, Antitrombin III</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Lupus
antikoagulan&#305;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Antikardiyolipin
antikorlar&#305;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Fakt�r V
Leiden mutasyonu</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Protrombin gen
mutasyonu</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center;line-height:150%'><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>4. Di&#287;er incelemeler</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Akut yerle&#351;en fokal n�rolojik bulgusu olan
bir hastada sinir sistemi<span style='color:red'> </span>infeksiyonu veya beyin
damarlar&#305;na ait vask�litik s�re� d�&#351;�n�l�yorsa beyin omurilik
s&#305;v&#305;s&#305; incelemesi&nbsp; yap&#305;lmal&#305;d&#305;r.<b> </b></span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ARTER
D&#304;SEKS&#304;YONU&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>T�m iskemik inmelerin yakla&#351;&#305;k % 2�sini
arter diseksiyonlar&#305; olu&#351;turur. Populasyon
�al&#305;&#351;malar&#305;nda y&#305;ll&#305;k diseksiyon insidensi &nbsp;2.6
-2.9 / 100.000 olarak bildirilmektedir. Arter diseksiyonlar&#305; spontan veya
travmatik olabilir. Biz burada spontan arter diseksiyonlar&#305;ndan s�z
edece&#287;iz. Diseksiyonlar&#305;n en s&#305;k g�r�ld�&#287;� ya&#351; 30-50
aras&#305;d&#305;r. Eri&#351;kinler aras&#305;nda s&#305;kl&#305;k
a�&#305;s&#305;ndan her iki cinste fark yoktur. Ancak diseksiyon
s&#305;ras&#305;nda kad&#305;nlar erkeklerden ortalama 5 y&#305;l daha gen�tir.
Arteryel diseksiyonlar&#305;n patogenezi bilinmemektedir. B�y�k
k&#305;sm&#305;nda �nemsiz bir travma s�z konusudur. Ani ba&#351; hareketleri,
�ks�rme, kusma, boyun manipulasyonu<span style='color:red'>, </span>intubasyon
uygulanmas&#305;, tavan boyama, yoga ve �e&#351;itli sportif aktiviteler
diseksiyon olu&#351;umunda rol oynayabilir. &nbsp;Ayr&#305;ca fibrom�sk�ler
displazi, Ehlers-Danlos sendromu, Marfan sendromu, otozomal dominant polikistik
b�brek hastal&#305;&#287;&#305;, osteogenezis imperfecta tip I gibi
arteriopatilerle birlikte g�r�lebilir. Spontan arteryel diseksiyonlu
hastalar&#305;n k���k bir k&#305;sm&#305;nda aile �yelerinden en az birinde
diseksiyon �yk�s� vard&#305;r. Migren, gebelik, oral kontraseptif
kullan&#305;m&#305;, hiperhomosistinemi, sigara ve hipertansiyon da spontan
arter<span style='color:red'> </span>diseksiyonu i�in risk fakt�rleridir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Arteryel diseksiyonlar intimal y&#305;rt&#305;lma
sonucu olu&#351;ur. Damar duvar&#305; y&#305;rt&#305;ld&#305;&#287;&#305;nda
kan, arter duvar&#305; aras&#305;na girerek �yalanc&#305; l�men�
olu&#351;turur. Yalanc&#305; l�men i�indeki kan artarak damar l�menini �nemli
�l��de daralt&#305;r veya lokal trombus olu&#351;mas&#305;na neden olur.
Olu&#351;an trombus sekonder olarak distal damarlarda embolizasyona&nbsp; yol
a�ar. Seyrek olarak yalanc&#305; anevrizma olu&#351;umu g�r�lebilir, ancak
anevrizmalar nadiren semptomatik olur.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kranyoservikal Arteryel Diseksiyon</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Spontan karotis diseksiyonlar&#305;n&#305;n&nbsp;
b�y�k b�l�m�nde&nbsp; hat&#305;rlanamayan �nemsiz bir travma s�z konusudur (
�e&#351;itli sportif aktiviteler, aniden yap&#305;lan boyun hareketleri gibi
).&nbsp; Karotis diseksiyonlar&#305;nda diseksiyon yeri a. carotis interna
(ICA)&nbsp; orijininin ilk 2 cm�lik b�l�m�n�n �st�ndedir. Diseksiyon
�o&#287;unlukla ICA�n&#305;n intrapetrozal k&#305;sm&#305;nda sona erer<span
style='color:red'>. </span>Buras&#305; b�y�k damar aterosklerozu i�in tipik bir
b�lge de&#287;ildir. Arter diseksiyonu ve b�y�k damar aterosklozunun
ay&#305;r&#305;c&#305; tan&#305;s&#305;nda lokalizasyon �nemlidir. Hastalarda
ipsilateral y�z, ba&#351; veya boyunda a&#287;r&#305; vard&#305;r. Bu
&#351;ikayetler iskemik belirtilerden birka� saat veya birka� hafta �nce
ortaya&nbsp; �&#305;kabilir.&nbsp; &#304;psilateral Horner sendromu
g�r�lebilir. Klinik bulgular ise a&#287;r&#305; ile birlikte ortaya �&#305;kan
karotis alan&#305;na ait G&#304;A veya inmelerdir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ekstrakranyal vertebral arter diseksiyonu spontan
arter&nbsp; diseksiyonlar&#305;n&#305;n g�r�ld�&#287;� en&nbsp; s&#305;k ikinci
lokalizasyondur. Boyun manipulasyonlar&#305; s&#305;ras&#305;nda ortaya
�&#305;kabilir. En s&#305;k g�r�ld�&#287;� yer ekstrakranyal vertebral arterin
C1-C2 d�zeyindeki V3&nbsp; segmentidir. Ba&#351; ve boyun a&#287;r&#305;s&#305;
ilk &#351;ik�yettir. Ba&#351; a&#287;r&#305;s&#305; s&#305;kl&#305;kla
oksipital b�lgede<span style='color:red'> </span>lokalizedir. &#304;skemik
belirtiler aras&#305;nda en s&#305;k lateral bulber&nbsp; ve serebellar enfarkt
g�r�l�r.</span><span lang=DE style='mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DE style='mso-ansi-language:
DE'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ekstrakranyal damar diseksiyonlar&#305;n&#305;n
tedavisi, bu konuda yap&#305;lm&#305;&#351; kontroll� randomize
�al&#305;&#351;malar bulunmad&#305;&#287;&#305;ndan
tart&#305;&#351;mal&#305;d&#305;r. Akut d�nemde intraven�z trombolitik
tedavinin emniyetle yap&#305;labilece&#287;ini belirten az say&#305;da vaka
bildirisi vard&#305;r. Bir �ok klinik 3 � 6 ay s�re ile antikoag�lan tedavi
uygulamaktad&#305;r. Biz de klini&#287;imizde 3 � 6 ay s�re ile antikoag�lan tedavi
uygulamaktay&#305;z . Antikoag�lan tedavi uygulanan olgularda INR de&#287;eri 2
� 3 aras&#305;nda tutulmal&#305;d&#305;r.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;ntrakranyal Arteryel Diseksiyon :</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Karotis ve vertebro-baziler&nbsp; sisteme ait
intrakranyal damarlarda diseksiyon olduk�a seyrektir. Vertebral arter ve baziler
artere ait intrakranyal diseksiyon, karotis sistemine ait intrakranyal
diseksiyonlardan daha s&#305;kt&#305;r. &#304;ntrakranyal diseksiyonlarda
serebral iskeminin yan&#305;s&#305;ra subaraknoid kanama da g�r�l�r. �zellikle
vertebro-baziler sistemdeki intrakranyal diseksiyon olgular&#305;nda subraknoid
kanama s&#305;kt&#305;r. Bu nedenle intrakranyal diseksiyon olgular&#305;nda
antikoag�lan tedavi uygulanmamal&#305;d&#305;r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Diseksiyon d�&#351;�n�len bir hastada ilk inceleme
olarak noninvasif bir inceleme olan Doppler US yap&#305;labilir. Ancak ya&#287;
bask&#305;lamal&#305; T1 a&#287;&#305;rl&#305;kl&#305; aksiyal MR incelemesi
diseksiyonu g�stermede olduk�a ba&#351;ar&#305;l&#305;d&#305;r (<b>&#350;ekil 1</b>)
. Bu incelemeye MRA da ilave edilirse arter l�menindeki daralma veya
t&#305;kanman&#305;n da&#287;&#305;l&#305;m&#305; ve uzunlu&#287;u
hakk&#305;nda daha iyi bilgi edinilebilir. Ayr&#305;ca yalanc&#305;<b> </b>anevrizma
olu&#351;mu&#351; ise g�r�lebilir. Konvansiyonel anjiyografi de diseksiyon
tan&#305;s&#305;nda ba&#351;vurulabilecek&nbsp;yard&#305;mc&#305; muayene
y�ntemidir (<b>&#350;ekil 2</b>).</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Diseksiyon saptanan olgularda ayn&#305; veya
farkl&#305; arter a&#287;ac&#305;nda rek�rrens �ok nadirdir. Ailesel vakalar
d&#305;&#351;&#305;nda y&#305;lda &nbsp;% 1 civar&#305;ndad&#305;r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;line-height:
150%'><b><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;line-height:
150%'><b><u><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;mso-ansi-language:TR'><a href="http://www.itfnoroloji.org/svh/rt1.jpg">&#350;ekil
1.</a></span></u></b><b><span lang=TR style='font-size:10.0pt;line-height:150%;
font-family:Tahoma;mso-ansi-language:TR'> </span></b><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Karotis diseksiyonunda MR incelemesi. Servikal b�lge ya&#287;
bask&#305;lamal&#305; T1 a&#287;&#305;rl&#305;kl&#305; MR incelemesinde aksiyal
planda al&#305;nan kesitlerde sa&#287; ICA�y&#305; �evreleyen beyaz renkte
intramural tromb�s g�r�l�yor (ok) &nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;line-height:
150%'><b><u><span lang=TR style='font-size:10.0pt;line-height:150%;font-family:
Tahoma;color:blue;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/rt2.jpg">&#350;ekil 2.</a></span></u></b><b><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;color:blue;
mso-ansi-language:TR'> </span></b><span lang=TR style='font-size:10.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Karotis
diseksiyonunda konvansiyonel anjiografi. Karotis anjiografisinde (lateral
g�r�n�m) sa&#287; ICA�n&#305;n incelerek t&#305;kand&#305;&#287;&#305;
g�r�l�yor (ok ba&#351;&#305;).</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;line-height:150%'><span lang=TR
style='font-size:11.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>MOYAMOYA
HASTALI&#286;I&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Moyamoya hastal&#305;&#287;&#305; serebral
anjiografide g�r�len, beyin bazalinde Willis poligonu �evresinde ve distalinde,
k���k anastomatik damar a&#287;&#305; ile birlikte her iki karotis arterinin terminal
par�alar&#305;n&#305;n darl&#305;k ve okl�zyonlar&#305; ile karakterizedir.
Kafa kaidesinde �ok fazla say&#305;da k���k kollateralin olu&#351;turdu&#287;u
g�r�n�me moyamoya denmi&#351;tir. Moyamoya Japoncada �sigara duman&#305;�
anlam&#305;na gelmektedir. Moyamoya hastal&#305;&#287;&#305;n&#305;n nedeni
bilinmemektedir. En s&#305;k Japonlarda g�r�l�r. Bu toplumda �ocuklarda
y&#305;ll&#305;k insidensi yakla&#351;&#305;k&nbsp; 3 / 100.000 olarak
bildirilmi&#351;tir. Di&#287;er toplumlarda daha seyrek g�r�l�r (Avrupa�da
Japonlar&#305;n 1 / 10�u). Erkek kad&#305;n oran&#305; 1: 1.8 d&#305;r. Japon
ara&#351;t&#305;r&#305;c&#305;lar ailevi bir e&#287;ilimden de s�z
etmi&#351;lerdir. En s&#305;k 10 ya&#351;&#305;n alt&#305;ndaki �ocuklarla,
&nbsp;40�l&#305; ya&#351;lar&#305;n ortalar&#305;ndaki eri&#351;kinleri
etkiler. �ocuklarda tekrarlayan iskemik olaylar, istemsiz hareketler,
yava&#351; ilerleyen mental y&#305;k&#305;m ve epileptik n�betler g�r�l�r.
Moyamoya hastal&#305;&#287;&#305; eri&#351;kinlerde iskemik inmenin
yan&#305;s&#305;ra intraserebral kanama, subaraknoid kanama, seyrek olarak da
intraventrik�ler kanamaya yol a�ar. Tan&#305; i�in konvansiyonel anjiyografi
gereklidir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Serebral anjiografide moyamoya g�r�n�m�
n�rofibromatozis, kranyal &#305;&#351;&#305;nlama, tuberoz skleroz, tuberk�loz
menenjiti, vask�litler,<span style='color:red'> </span>Down sendromu ile
birlikte bulunabilir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Moyamoya hastal&#305;&#287;&#305;n&#305;n kesin
bir tedavisi yoktur. &#304;nme i�in risk fakt�rlerinin kontrol�, hipotansiyon
ve hiperventilasyondan ka�&#305;nmak iskemik inmeden korunmak i�in �nemlidir.
Cerrahi olarak direkt ve indirekt revask�larizasyon y�ntemleri ile koruyucu
tedavi giri&#351;imleri<span style='color:red'> </span>�nerilmektedir.<span
style='color:red'> </span>Direkt revask�larizasyon i�in en s&#305;k superfisyal
temporal arter ile a.serebri media aras&#305;nda bypass
yap&#305;lmaktad&#305;r. &#304;ndirekt revask�larizasyonda EDAS (ensefaloduroarteriosinanjiosis)
ve EDAMS (ensefaloduroarteriomiyosinanjiosis) gibi y�ntemler
kullan&#305;lmaktad&#305;r. Cerrahi revask�larizasyonlar&#305;n
hastal&#305;&#287;&#305;n prognozu �zerine olan etkileri kesin olarak
bilinmemektedir.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>TAKAYASU &nbsp;HASTALI&#286;I</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Takayasu hastal&#305;&#287;&#305;
(Nab&#305;zs&#305;zl&#305;k hastal&#305;&#287;&#305;, idyopatik aortitis) aorta
ve dallar&#305; ile seyrek olarak pulmoner arterleri tutan nedeni bilinmeyen
kronik inflamatuvar gran�lomat�z arterittir. Hastal&#305;k b�y�k ve orta boy
arterleri tutar. Karotisler, subklavya, brakiyosefalik arterler etkilenir.
&#304;ntrakranyal damarlar nadiren tutulur. S&#305;kl&#305;kla 11-30 ya&#351;
aras&#305;ndaki gen� kad&#305;nlarda (% 75) g�r�l�r. En s&#305;k Asya
toplumlar&#305;nda rastlan&#305;r.&nbsp; </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yorgunluk, miyalji, artralji, ate&#351;, anemi ve
kilo kayb&#305; gibi akut faz belirtileri vard&#305;r. Ayn&#305; d�nemde veya
daha sonra arterlerin stenoz ve okl�zyonlar&#305;na veya hipertansiyona
ba&#287;l&#305; olarak hastalar&#305;n yakla&#351;&#305;k % 70� inde
kardiyovask�ler ve serebrovask�ler belirtiler geli&#351;ir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kol klodikasyosu, ba&#351; d�nmesi (dizziness ) ve
senkop en s&#305;k belirtilerdir. Ba&#351; d�nmesi ve senkop post�ral
de&#287;i&#351;ikliklerden sonra ortaya �&#305;kabilir (yatar pozisyondan
oturur duruma ge�me veya aya&#287;a kalkma gibi). Ge�ici g�rme
bulan&#305;kl&#305;&#287;&#305;, amorozis fugaks gibi viz�el belirtiler de
erken d�nemde s&#305;k g�r�l�r. Subklavya �alma sendromu s&#305;k g�r�lmesine
kar&#351;&#305;n, muhtemelen Willis poligonunun iyi �al&#305;&#351;mas&#305;
sonucu arka sistem iskemisine pek rastlanmaz. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Beyin infarkt&#305;na hastal&#305;&#287;&#305;n
ileri d�nemlerinde rastlan&#305;r. Radyal nab&#305;z&#305;n palpe edilememesi
erken d�nemde �nemli bir belirtidir. Ayr&#305;ca her iki kol aras&#305;nda
belirgin kan bas&#305;nc&#305; fark&#305; saptanabilir.<span style='color:red'>
</span>Kol ve bacak kan bas&#305;n�lar&#305; aras&#305;nda da asimetri g�r�l�r.
A.subklavya stenozuna ba&#287;l&#305; olarak �st ekstremitelerde kan
bas&#305;nc&#305; daha d�&#351;�kt�r. Hipertansiyona ba&#287;l&#305; olarak
intraserebral kanamalar geli&#351;ebilir. Supraklavik�ler b�lge ve karotisler
�zerinde �f�r�m duyulabilir. Konjestif kalp yetmezli&#287;i ve hipertansiyon
geli&#351;ir. Hipertansiyon en s&#305;k<span style='color:red'> </span>belirtilerden
biridir ve renal arterlerin stenozuna ba&#287;l&#305;d&#305;r. Erken d�nemde ve
akut fazda sedimentasyon y�ksektir. Sedimentasyon s&#305;kl&#305;kla kronik
d�nemde veya kortikosteroid tedavisi ile normale d�ner. C � reaktif protein
hastal&#305;&#287;&#305;n aktivitesini izlemek a�&#305;s&#305;ndan �nemli bir
indikat�rd�r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Erken ve akut d�nemde glikokortikoidlerin
inflamasyonu �nlemede etkili oldu&#287;u belirtilmi&#351;tir. Siklofosfamid
veya metotreksat&nbsp; kortikosteroidlere iyi yan&#305;t vermeyen hastalarda
kullan&#305;labilir. Kronik d�nemde �e&#351;itli cerrahi rekonstr�ksiyonlar
uygulanmaktad&#305;r. Son zamanlarda renal arterlere ve beyin damarlar&#305;na
stent uygulamas&#305; yap&#305;lmaktad&#305;r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ANT&#304;FOSFOL&#304;P&#304;D ANT&#304;KOR
SENDROMU ( APS )</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Antifosfolipidler belirli fosfolipidlere
kar&#351;&#305; olu&#351;an poliklonal antikorlard&#305;r. En s&#305;k
g�r�lenleri lupus antikoag�lan&#305; (LA) ve antikardiyolipin
antikorlar&#305;d&#305;r. Antifosfolipid antikorlar&#305; bazen sistemik lupus
eritematozus (SLE) ile birlikte olabilir. Ancak hastalar&#305;n b�y�k bir
k&#305;sm&#305;nda SLE�nin serolojik ve klinik&nbsp; �zellikleri g�r�lmez. Buna
primer antifosfolipid sendromu ad&#305; verilir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sa&#287;l&#305;kl&#305; ki&#351;ilerde&nbsp;
antifosfolipid antikorlar&#305;n&#305;n prevalans&#305; % 0-2
aras&#305;ndad&#305;r. Bunun yan&#305;s&#305;ra SLE, di&#287;er kollagen
vask�ler hastal&#305;klar, maliniteler, lenfoma, paraproteinemiler, H&#304;V ve
di&#287;er infeksiyonlar, baz&#305; ila�lar&#305;n kullan&#305;lmas&#305;nda
(fenotiazin, fenitoin, valproat, prokainamid, kinidin) da antikorlar y�ksek
bulunabilir. &nbsp;Ancak iskemik inmeli gen� hastalar aras&#305;nda&nbsp;
prevalans y�ksektir. APASS (Antiphospholipid Antibodies in Stroke Study Group)
grubu,&nbsp; ilk iskemik inmeli olgularda antikardiolipin
antikorlar&#305;n&#305;n y�ksek olmas&#305;n&#305;n ba&#287;&#305;ms&#305;z
risk fakt�r� olu&#351;turdu&#287;unu g�stermi&#351;tir.&nbsp; Antifosfolipidler
IgG, IgM, IgA gibi immunoglobulinlerdir. �e&#351;itli&nbsp;
�al&#305;&#351;malarda retinal veya serebral iskemili hastalarda IgG�nin IgM�ye
g�re anlaml&#305; derecede y�ksek bulundu&#287;u g�sterilmi&#351;tir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Primer antifosfolipid antikor sendromunda
tekrarlayan d�&#351;�kler, �l� do&#287;umlar, de&#287;i&#351;ik �aptaki
damarlarda arteriyel ve ven�z trombozlar, livedo retik�laris, kalp
kapa&#287;&#305; vejetasyonlar&#305;, migrene benzer ba&#351;
a&#287;r&#305;lar&#305;, trombositopeni, yalanc&#305; pozitif sifiliz testi
ba&#351;l&#305;ca bulgulard&#305;r. &#304;skemik olaylar&#305;n nedeni
s&#305;kl&#305;kla trombotiktir<span style='color:red'>. </span>Ancak kalp
kapaklar&#305;nda olu&#351;an vejetasyonlara ba&#287;l&#305; olarak embolik
inmeler de olu&#351;abilir.&nbsp; En s&#305;k mitral kapak tutulur. APS
d�&#351;�n�len bir hastada, antikorlar normal ise, birka� hafta sonra inceleme
tekrarlanmal&#305;d&#305;r. Akut atak s&#305;ras&#305;nda antikor titresi
d�&#351;�k bulunabilir. Primer APS�li hastalar&#305; trombozdan korumak i�in
s&#305;kl&#305;kla antikoag�lan tedavi uygulanmaktad&#305;r. INR degeri
yakla&#351;&#305;k 3 . 0 civar&#305;nda tutulmal&#305;d&#305;r. APS�li iskemik
inmeli hastalar&#305; rek�rren inmeden korumak i�in antiagregan veya&nbsp;
antikoag�lan tedavinin �st�nl�&#287;� konusunda kesin bilgi yoktur. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>SNEDDON SENDROMU</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;skemik inme ve livedo retik�laris�in&nbsp;
birlikte bulunmas&#305;na Sneddon sendromu ad&#305; verilir. Ancak bu
tan&#305;y&#305; koyabilmek i�in livedo retik�larise neden olabilen konnektif
doku hastal&#305;&#287;&#305;, inflamatuvar hastal&#305;klar ve
infeksiyonlar&#305;n d&#305;&#351;lanmas&#305; gerekir. Livedo retik�laris
morumsu-k&#305;rm&#305;z&#305; renkte, retik�ler paternde k�tane lezyondur.
G�vde ve ekstremitelerde yer al&#305;r.Y�zde g�r�lmez. Hastalar&#305;n % 40 �
&#305;nda antifosfolipid antikorlar&#305; ve antiendotelyal antikorlar
saptanabilir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sneddon sendromlu hastalarda livedo retik�laris
inmeden �ok �nce g�r�lebilir. Hastalar&#305;n b�y�k �o&#287;unlu&#287;u
kad&#305;n ve hipertansiftir. Beyin damar hastal&#305;klar&#305;
s&#305;kl&#305;kla 40�l&#305; ya&#351;larda g�r�l�r. Beyin damar
hastal&#305;klar&#305; i�inde en s&#305;k g�r�len tekrarlayan inmelerdir.
G&#304;A,epilepsi n�beti &nbsp;ve demans da bildirilmi&#351;tir.<span
style='color:red'> </span>Vakalar&#305;n �o&#287;unda hiperkoag�labilite �nemli
rol oynar.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;page-break-after:
avoid'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>HOMOS&#304;ST&#304;NEM&#304;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Homosistinemi ba&#351;l&#305;ca �cystathionine
beta synthase�&nbsp; eksikli&#287;inin&nbsp; yol a�t&#305;&#287;&#305;
metiyonin metabolizmas&#305; bozuklu&#287;u&nbsp; sonucu ortaya �&#305;kan,
otozomal resesif bir bozukluktur. Serebral arteryel ve ven�z tromboz
e&#287;ilimini&nbsp; artt&#305;r&#305;r. Sistatiyonin beta sentaz�&nbsp;
eksikli&#287;inin prevalans&#305; 1/80.000- 1/200.000 aras&#305;nda
de&#287;i&#351;mektedir, homozigot ve heterozigot olmak �zere iki tipi
vard&#305;r.. Homozigot tipinde marfanoid tipte v�cut yap&#305;s&#305;, lens
dislokasyonu, mental retardasyon ve epileptik n�betler g�r�l�r. Heterozigot
tipi veya edinsel metiyonin metobolizma bozukluklar&#305; sonucu ortaya
�&#305;kan homosistinemilerde inme riskinde art&#305;&#351;&nbsp; g�r�l�r.
Edinsel homosistinemi ise ileri ya&#351;, hiperlipidemi, sigara, diabetes
mellitus, kronik renal yetesizlik, hipertansiyonla birlikte g�r�lebilir.
Ayr&#305;ca vitamin eksikli&#287;inde de ortaya �&#305;kabilir. (B6, folik
asit, B12 gibi). Edinsel homosistineminin tedavisinde B6, folik asit ve B12
vitaminleri verilmelidir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>MELAS </span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>(<b>M</b>itochondrial Myopathy, <b>E</b>ncephalopathy, <b>L</b>actic&nbsp; <b>A</b>cidosis
and <b>S</b>troke like Episodes)</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>MELAS, mitokondriyal miyopati, ensefalopati,
laktik asidoz, inmeye benzer epizodlarla&nbsp; karakterize, mitokondriyal
DNA�da mutasyon sonucu&nbsp; ortaya �&#305;kan, herediter bir
hastal&#305;kt&#305;r. K&#305;sa boy, tekrarlayan inmeye benzer epizodlar,
epilepsi, migren tipi ba&#351; a&#287;r&#305;lar&#305; ba&#351;l&#305;ca
belirtileridir. Migren tipi ba&#351; a&#287;r&#305;lar&#305; inme
epizodlar&#305;ndan �nce ortaya �&#305;kar. Hastalarda daha sonra demans
geli&#351;ir. �ocuklarda, gen�lerde veya orta ya&#351;l&#305; ki&#351;ilerde
g�r�lebilir. Serumda ve beyin omurilik s&#305;v&#305;s&#305;nda laktat d�zeyi
y�ksektir. BT�de bazal ganglia kalsifikasyonu, serebral hemisferlerin gri ve
beyaz maddesinde hipodens alanlar vard&#305;r. Akut d�nemde kitle etkisi olan
ve kontrast madde tutan bu lezyonlar daha sonra kaybolur. Bu bulgular kranyal
MR�da&nbsp; daha belirgin olarak g�sterilebilir. Kas biopsisinde, kasta
mitokondriyal hastal&#305;kla uyumlu �<i>ragged red fiber</i>��lar g�r�l�r
(Bak&#305;n&#305;z: <u><a href="http://www.itfnoroloji.org/kas/kasindex.htm">Kas
ve N�rom�sk�ler Kav&#351;ak Hastal&#305;klar&#305;</a></u>). Spesifik bir
tedavisi yoktur. </span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;page-break-after:
avoid'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;page-break-after:
avoid'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>CADASIL
</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>(<b>C</b>erebral
<b>A</b>utosomal <b>D</b>ominant <b>A</b>rteriopathy with <b>S</b>ubcortical <b>I</b>nfarcts
and <b>L</b>eukoencephalopathy)</span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ondokuzuncu </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>kromozomdaki&nbsp;
notch 3 geninde mutasyon sonucu ortaya �&#305;kan herediter, otozomal dominant,
k���k damarlar&#305; tutan bir hastal&#305;kt&#305;r. Genetik lokus ilk olarak
2 Frans&#305;z ailede g�sterilmi&#351;tir. Orta ya&#351;ta ba&#351;lar. Tekrarlayan
iskemik epizodlar g�r�l�r. &#304;skemik belirtiler G&#304;A veya lak�ner inme
&#351;eklindedir. Daha sonra ps�dobulber belirtiler ve subkortikal demans
geli&#351;ir. &#304;lk&nbsp; iskemik belirtilerin g�r�lmesinden&nbsp;
yakla&#351;&#305;k 10 y&#305;l sonra hastalar kaybedilir. Hastalar&#305;n
%40�&#305;nda aural&#305; veya auras&#305;z migren ataklar&#305; vard&#305;r.
Bunlar hastal&#305;&#287;&#305;n ilk belirtisi olabilir. &#304;skemik
belirtilerin g�r�lmesinden y&#305;llar �nce psikiyatrik belirtiler ve
davran&#305;&#351; de&#287;i&#351;iklikleri g�r�lebilir.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>MR hastal&#305;&#287;&#305;n tan&#305;s&#305;nda
�ok �nemlidir. Semptomatik ki&#351;ilerde hemen daima patolojiktir .&nbsp;
MR�da patolojik sinyal de&#287;i&#351;iklikleri hasta semptomatik olmadan �nce
de saptanabilir. MR�da&nbsp; subkortikal beyaz maddede ve bazal gangliada k���k
derin infarktlar g�r�lebilir. CADASIL�de kortikal tutulum ve infratentoryal
lezyonlar �ok nadirdir. Ayr&#305;ca periventrik�ler ve subkortikal beyaz
maddede fokal veya diff�z patolojik sinyal art&#305;&#351;&#305; vard&#305;r.
Temporal loblarda g�r�lebilen patolojik sinyal de&#287;i&#351;ikli&#287;i
ay&#305;r&#305;c&#305; tan&#305;da �nemlidir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Beynin perforan ve leptomenengeal
damarlar&#305;nda eozinofilik materyal depolanmas&#305; vard&#305;r. Elektron
mikroskobunda etkilenen damarlar&#305;n bazal laminas&#305;nda gran�ler
osmiofilik materyal birikimi g�sterilmi&#351;tir. Benzer
de&#287;i&#351;iklikler deri, kas ve sinirde de bulunabilir Hastal&#305;&#287;&#305;n
bilinen bir tedavisi yoktur. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;page-break-after:
avoid'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;page-break-after:
avoid'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>PATENT
FORAMEN OVALE VE ATR&#304;AL SEPTAL ANEVR&#304;ZMA</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Patent foramen ovalenin (PFO)
sa&#287;l&#305;kl&#305; ki&#351;ilerdeki prevalans&#305; %20-25
aras&#305;ndad&#305;r. Gen� iskemik inmeli hastalarda s&#305;k g�r�lmesine
kar&#351;&#305;n, parodoksal emboli yoluyla iskemiye yol a�mas&#305; �ok
nadirdir.<span style='color:red'> </span>Tek ba&#351;&#305;na PFO�su bulunan
hastalarda ise inme rek�rrensi d�&#351;�kt�r (%1� 2 / y&#305;lda). Ancak
beraberinde atriyal septal anevrizma (ASA) varsa veya hasta birden fazla inme
ge�irmi&#351; ise rek�rrens riski belirgin olarak artmaktad&#305;r. PFO
tedavisinde antiagregan, antikoag�lan tedaviler ile septumun cerrahi veya
endovask�ler olarak kapat&#305;lmas&#305; �nerilmektedir. Varfarin ile aspirini
kar&#351;&#305;la&#351;t&#305;ran bir �al&#305;&#351;mada varfarinin hem PFO�lu
hem de PFO ve ASA� n&#305;n birlikte bulundu&#287;u hastalarda rek�rren inmeyi
�nlemede ilave bir katk&#305; sa&#287;lamad&#305;&#287;&#305; g�sterilmi&#351;tir.
&#304;nme rek�rrensinin y�ksek oldu&#287;u d�&#351;�n�len hastalarda atriyal
septal anevrizma olsa da olmasa da PFO�nun endovask�ler olarak
kapat&#305;lmas&#305; �nerilmektedir ve bunun medikal tedaviye g�re inme
riskini azaltt&#305;&#287;&#305; ileri s�r�lmektedir. Ancak bu konuda randomize
klinik �al&#305;&#351;malara ihtiya� vard&#305;r.&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>M&#304;TRAL VALV
PROLAPSUSU (MVP)</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mitral valv prolapsusu ( MVP )
sa&#287;l&#305;kl&#305; ki&#351;ilerde klinik ve ekokardiografilerde s&#305;k
rastlanan bir bulgudur. Familyal olabilir. Tan&#305; kriterleri&nbsp; �ok
de&#287;i&#351;ik olabildi&#287;i i�in&nbsp; MVP prevalans&#305; �e&#351;itli
serilerde de&#287;i&#351;iklik g�stermektedir. MVP kad&#305;nlarda %20,
erkeklerde %10 oran&#305;nda bildirilmektedir. &#304;skemik inmeli hastalarda
MVP s&#305;kl&#305;&#287;&#305; beklenenden daha s&#305;k bulunmam&#305;&#351;t&#305;r.
MVP�de inme riski y&#305;lda %0.001�den daha az olarak hesaplanmaktad&#305;r.
Komplike olmayan MVP emboli kayna&#287;&#305; olarak d�&#351;�n�lmemektedir.
MVP ile birlikte, belirgin mitral reg�rjitasyon, atriyal fibrilasyon veya
infektif endokardit varsa, MVP emboli kayna&#287;&#305; olarak
d�&#351;�n�lmektedir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;page-break-after:
avoid'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>M&#304;GREN
/ &#304;NME</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Migrene ba&#287;l&#305; inme olduk�a nadirdir.
Aural&#305; migreni oldu&#287;u bilinen bir ki&#351;ide, tipik migren
ata&#287;&#305; s&#305;ras&#305;nda inme geli&#351;irse, migren ile inme
aras&#305;nda ili&#351;ki kurulabilir. Ancak ortaya �&#305;kan n�rolojik
defisitin daha �nceki migren ataklar&#305; s&#305;ras&#305;nda g�r�len belirti
ile benzer olmas&#305; ve inmeye yol a�abilecek t�m etyolojik nedenlerin
d&#305;&#351;lanmas&#305; gerekmektedir. Migren ile ili&#351;kili inme en
s&#305;k a. cerebri posterior&nbsp; sulama alan&#305;nda g�r�l�r. &#304;nme,
migren ata&#287;&#305; s&#305;ras&#305;nda ortaya �&#305;kabilece&#287;i gibi
bir migren ata&#287;&#305;n&#305; da ba&#351;latabilir. Toplumda gerek migren,
gerekse inme s&#305;k g�r�ld�&#287;�nden her iki durum rastlant&#305;sal olarak
bir arada olabilir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>KAYNAKLAR</span></b></p>

<p class=MsoNormal><span style='font-family:Tahoma'>&nbsp;</span></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal style='mso-list:l1 level1 lfo3;tab-stops:list 36.0pt'><span
     style='font-family:Tahoma'>APASS GROUP. Antiphospholipid Antibodies in
     Stroke Study Group: Clinical and laboratory findings in patients with antiphospolipid
     antibodies and cerebral ischemia. Stroke 1990;&nbsp; 21:1268-73. </span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo3;tab-stops:list 36.0pt'><span
     style='font-family:Tahoma'>Antiphospholipid Antibodies in Stroke Study
     (APASS) Group. Anticardiolipin antibodies are an independent risk factor
     for first ischemic stroke. Neurology&nbsp; 1993; 43:2069-73. </span></li>
</ol>

<ol style='margin-top:0cm' start=2 type=1>
 <li class=MsoNormal style='mso-list:l3 level1 lfo6;tab-stops:list 36.0pt'><span
     style='font-family:Tahoma'>Barnet HJM, Mohr SP, Stein BM, Yatsu FM (eds):
     Stroke. Pathophysiology, Diagnosis and Management (3rd ed). New York,
     Churchill Livingstone, 1998. </span></li>
 <li class=MsoNormal style='mso-list:l3 level1 lfo6;tab-stops:list 36.0pt'><span
     style='font-family:Tahoma'>Bogousslavsky J, Caplan LR (eds): Stroke
     Syndromes (2 nd ed). Cambridge, Cambridge University Press, 2001. </span></li>
 <li class=MsoNormal style='mso-list:l3 level1 lfo6;tab-stops:list 36.0pt'><span
     style='font-family:Tahoma'>Bogousslavsky J, Caplan L (eds): Uncommon
     Causes of Stroke (1<sup>st</sup> ed). Cambridge, Cambridge University
     Press, 2001. </span></li>
 <li class=MsoNormal style='mso-list:l3 level1 lfo6;tab-stops:list 36.0pt'><span
     style='font-family:Tahoma'>Fisher M (ed): Clinical Atlas of
     Cerebrovascular Disorders. London, Mosby, 1994. </span></li>
 <li class=MsoNormal style='mso-list:l3 level1 lfo6;tab-stops:list 36.0pt'><span
     style='font-family:Tahoma'>Mas TL, Arquizan C, Lamy C, Zuber M, Canabes L,
     Derumaux G, Costes. J. Recurrent cerebrovascular events associated with
     patent foramen ovale, atrial septal aneurysm, or both. N Eng J Med 2001;
     345: 1740-1746. </span></li>
 <li class=MsoNormal style='mso-list:l3 level1 lfo6;tab-stops:list 36.0pt'><span
     style='font-family:Tahoma'>Mohr JP ,Choi DW ,Grotta JC ,Weir B , Wolf PA
     (eds ) : Stroke . Pathophysiology , Diagnosis and Management (4<sup>th</sup>
     ed ). New York, Churchill Livingstone, 2004</span></li>
 <li class=MsoNormal style='mso-list:l3 level1 lfo6;tab-stops:list 36.0pt'><span
     style='font-family:Tahoma'>Warlow CP,Dennis MS, van Gijn J, Hankey GT,
     Sandercock PAG, Bamford JM, Wardlaw J (eds): Stroke: A Practical Guide to
     Management (3<sup>rd</sup> Ed). Oxford, Blackwell Science, 2008. </span></li>
</ol>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:12.0pt'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><br>
<br style='mso-special-character:line-break'>
<![if !supportLineBreakNewLine]><br style='mso-special-character:line-break'>
<![endif]></span></p>

</div>

</body>

</html>
